LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | AZD-6482 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 4380 | 5905 | 0.7408 | 0.7310 |
| SK-BR-3 | YM 201636 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5952 | 5752 | 1.0348 | 1.0591 |
| MCF7 | AZD-6482 | 10 | uM | LJP5 | 72 | hr | 1389 | 1957 | 5905 | 0.3309 | 0.1761 |
| MCF7 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 4291 | 5905 | 0.7258 | 0.7143 |
| MCF7 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 5148 | 5905 | 0.8727 | 0.8738 |
| MCF7 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 4606 | 5905 | 0.7791 | 0.7735 |
| MCF7 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 3747 | 5905 | 0.6343 | 0.6078 |
| MCF7 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 3143 | 5905 | 0.5323 | 0.4785 |
| MCF7 | Linsitinib | 10 | uM | LJP5 | 72 | hr | 1389 | 2659 | 5905 | 0.4506 | 0.3651 |
| MCF7 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5760 | 5905 | 0.9765 | 0.9775 |
| MCF7 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 5443 | 5905 | 0.9227 | 0.9245 |
| MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 5681 | 5905 | 0.9629 | 0.9643 |
| MCF7 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 6306 | 5905 | 1.0669 | 1.0620 |
| MCF7 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 6160 | 5905 | 1.0434 | 1.0412 |
| MCF7 | Ruxolitinib | 10 | uM | LJP5 | 72 | hr | 1389 | 4975 | 5905 | 0.8428 | 0.8428 |
| MCF7 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5533 | 5905 | 0.9370 | 0.9386 |
| MCF7 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 5704 | 5905 | 0.9670 | 0.9682 |
| MCF7 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 5393 | 5905 | 0.9143 | 0.9161 |
| MCF7 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 4328 | 5905 | 0.7332 | 0.7238 |
| MCF7 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 3516 | 5905 | 0.5952 | 0.5595 |
| MCF7 | Momelotinib | 10 | uM | LJP5 | 72 | hr | 1389 | 1687 | 5905 | 0.2856 | 0.0968 |
| MCF7 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6059 | 5905 | 1.0265 | 1.0254 |
| MCF7 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 6029 | 5905 | 1.0212 | 1.0204 |
| SK-BR-3 | PF477736 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 1575 | 5752 | 0.2738 | -0.3345 |
| SK-BR-3 | PF477736 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 1652 | 5752 | 0.2872 | -0.3070 |